Scott Tagawa
Professor - Medicine Weill Cornell Medicine
Scott T. Tagawa, MD, MS, FACP, FASCO, is a Professor of Medicine and Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center. After earning his BS from Georgetown University, Dr. Tagawa received his Medical Degree at the University of Southern California (USC) School of Medicine. After completing his Internship and Residency training at USC, he became Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years. Dr. Tagawa had the opportunity to train with international leaders in Genitourinary (GU) Oncology. In August 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary (GU) Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medicine (WCM) in 2007. His research covers clinical and translational investigations in genitourinary tumors and thrombosis (blood clotting) in people with cancer. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer. Dr. Tagawa also serves as leader of the GU Disease Management Team and co-leader of the Experimental Therapeutics Program of the Meyer Cancer Center. He is the WCM principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple “top doctor” award lists.
Seminars
It is widely considered that there is no single “Silver Bullet” that can be a widely received oncology treatment, ADCs and RLTs alike. With all therapies having their own specific drawbacks and therapeutic indices to take into account, a synergistic approach may be the best way to attack cancer from different biological angles.
Combination and multimodal approaches – pairing alpha and beta emitters or integrating RLT with PARP inhibitors or antibody-drug conjugates can enhance efficacy, reduce doses, and extend progression-free survival.
This session explores strategies to implement tandem and multimodal RLT approaches in the clinic, translating preclinical insights into safer, more effective patient care.
- Sequencing and synergy to optimize order and combination of therapies
- Patient selection using biomarkers, genomics, and receptor profiling
- Safety and efficacy balancing toxicity with therapeutic benefit
- Operational readiness ensuring supply chain and radiopharmacy reliability
–
Outcome – Design a clinical roadmap for various potential combination partners for RLTs.
